RT Journal Article
SR Electronic
T1 The SARS-CoV2 pandemic explained via asymptomatic infection and susceptibility heterogeneity. Buenos Aires first wave
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21255801
DO 10.1101/2021.04.26.21255801
A1 Bullo, Manuela
A1 Poy-Piñeiro, Santiago
A1 Cosatto-Ammann, Pedro
A1 Seoane, Hernan
A1 Picasso, Emilio
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.26.21255801.abstract
AB Background The rapid global spread of SARS-COV-2 forced governments to implement drastic interventions. The existence of a large but undetermined number of mild or non-symptomatic but infectious cases seems to be involved in the rapid spread, creating a high level of uncertainty due to the difficulty to measure them, and difficulty for epidemiologic modelling.Methods We developed a compartmental model with deterministic equations, that accounts for clinical status, mobility, r heterogenous susceptibility and non-pharmaceutical interventions. The model was calibrated using data from different regions and we used it to predict the dynamic in Buenos Aires Metropolitan Area (AMBA).Results The model adjusted well to different geographical regions. In AMBA the model predicted 21400 deaths at 300 days, with 27% of the population in the region immunized after the first wave, partly due to the high incidence of asymptomatic cases. The mobility restriction is approximately linear, with any restriction bringing a positive effect. The other interventions have a combined effect of 27% reduction in infection rates.Conclusion Our research underlines the role of asymptomatic cases in the epidemics’ dynamic and introduces the concept of susceptibility heterogeneity as a potential explanation for otherwise unexplained outbreak dynamics. The model also shows the big role of non-pharmaceutical interventions both in slowing down the epidemic dynamics and in reducing the eventual number of deaths. The model results are closely compatible with observed data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted using public data from open sources and did not require a specific IRB approval, in accordance with relevant guidelinesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for this paper is available upon request